Search Results

Karuna Therapeutics, Inc. (NASDAQ: KRTX) and GFB (ABC), LLC, assignee of the Goldfinch Bio assignment estate, today announced their entry into an exclusive license agreement under which Karuna will obtain global development, manufacturing, and commercialization rights to Goldfinch Bio’s investigational transient receptor potential canonical 4 and 5 (TRPC4/5) channel candidates, including lead clinical-stage candidate GFB-887.

Karuna Therapeutics acquired exclusive rights to Goldfinch Bio’s investigational TRPC4/5 channel candidates in a deal potentially worth $520 million.

Goldfinch Bio today announced that Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will participate in a panel discussion, Casino Re-nal – Novel Mechanisms in Renal Disorders , at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 9, 2022.

About a month after reporting it’s had a tough time starting enough patients on its treatments, bluebird bio announced it will lay off about 25% of its employees, over half of whom work in R&D.

With the addition of NTx’s co-founder and former President to the board Mercury Bio significantly enhances its strategic reach in the biotech sector

Facing financial challenges, IN8bio is looking to preserve cash resources through a pipeline prioritization and layoffs at its New York City and Birmingham, Alabama, sites.

Aruna Bio, Inc. announced that Stephen From, Chief Executive Officer of Aruna Bio, will be presenting a corporate overview at the 2024 BIO International Convention being held June 3-6, 2024 at the San Diego Convention Center, California.

Matica Biotechnology (Matica Bio) announced today that it will participate in the world’s largest biotech exhibition, the BIO International Convention (BIO USA).

BlueSphere Bio today announced that Keir Loiacono, Esq., Chief Executive Officer of BlueSphere Bio, will provide a corporate update and participate in a panel discussion at the 2024 BIO International convention being held from June 3 – 6, 2024.

Novartis continues its dealmaking spree with a bet on Dren Bio’s Targeted Myeloid Engager and Phagocytosis platform to develop bispecific antibodies in oncology.